Cardiac Failure Review最新文献_第5页

Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy. 钠-葡萄糖共转运蛋白2抑制剂在保留射血分数的心力衰竭中的应用:成功治疗的基本原理和实际应用。

Cardiac Failure Review Pub Date : 2022-07-08 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2022.04

Mauro Gori, Emilia D'Elia, Edoardo Sciatti, Michele Senni

{"title":"Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy.","authors":"Mauro Gori, Emilia D'Elia, Edoardo Sciatti, Michele Senni","doi":"10.15420/cfr.2022.04","DOIUrl":"https://doi.org/10.15420/cfr.2022.04","url":null,"abstract":"Heart failure (HF) with preserved left ventricular ejection fraction is a common disease with a poor prognosis and rising prevalence in the community. The current paradigm of treatment includes symptomatic therapy, such as diuretics, and risk factor control and treatment of comorbidities. According to European guidelines, there is no effective therapy for patients with HF with left ventricular ejection fraction (LVEF) ≥50%, while drugs normally used in HF with reduced LVEF might also be effective for patients with mildly reduced LVEF (40-50%), with a IIB class of recommendation. The recently published EMPEROR-Preserved trial has challenged current guidelines, demonstrating improved outcomes in patients with HF and LVEF >40% with the sodium-glucose cotransporter 2 inhibitor (SGLT2I) empagliflozin, compared with placebo. This result was consistent in patients with and without diabetes as well as in those with LVEF below and above 50%. The authors describe the rationale for this therapy, presenting the main results of the EMPEROR-Preserved trial, and provide some recommendations for the everyday clinical management of HF with preserved left ventricular ejection with an SGLT2I.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":" ","pages":"e26"},"PeriodicalIF":0.0,"publicationDate":"2022-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0d/e9/cfr-08-e26.PMC9295008.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40529358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unequitable Heart Failure Therapy for Black, Hispanic and American-Indian Patients. 黑人、西班牙裔和美国印第安人患者的不公平心力衰竭治疗。

Cardiac Failure Review Pub Date : 2022-07-07 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2022.02

Onyedika Ilonze, Kendall Free, Khadijah Breathett

引用次数: 14

Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis. 射血分数保留型心力衰竭的微血管功能障碍：病理生理学、评估、发病率和预后。

IF 4.2

Cardiac Failure Review Pub Date : 2022-07-01 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2022.12

Joanna M Bilak, Uazman Alam, Christopher A Miller, Gerry P McCann, Jayanth R Arnold, Prathap Kanagala

引用次数: 0

Clinical Evidence and Proposed Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect? 钠-葡萄糖共转运蛋白2抑制剂在保留射血分数的心力衰竭中的临床证据和机制:一类效应?

Cardiac Failure Review Pub Date : 2022-06-29 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2022.11

Brent Deschaine, Sahil Verma, Hussein Rayatzadeh

{"title":"Clinical Evidence and Proposed Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?","authors":"Brent Deschaine, Sahil Verma, Hussein Rayatzadeh","doi":"10.15420/cfr.2022.11","DOIUrl":"https://doi.org/10.15420/cfr.2022.11","url":null,"abstract":"Effective treatment for heart failure with preserved ejection fraction (HFpEF) is an unmet need in cardiovascular medicine. The pathophysiological drivers of HFpEF are complex, differing depending on phenotype, making a one-size-fits-all treatment approach unlikely. Remarkably, sodium-glucose cotransporter 2 inhibitors (SGLT2is) may be the first drug class to improve cardiovascular outcomes in HFpEF. Randomised controlled trials suggest a benefit in mortality, and demonstrate decreased hospitalisations and improvement in functional status. Limitations in trials exist, either due to small sample sizes, differing results between trials or decreased efficacy at higher ejection fractions. SGLT2is may provide a class effect by targeting various pathophysiological HFpEF mechanisms. Inhibition of SGLT2 and Na+/H+ exchanger 3 in the kidney promotes glycosuria, osmotic diuresis and natriuresis. The glucose deprivation activates sirtuins - protecting against oxidation and beneficially regulating metabolism. SGLT2is reduce excess epicardial adipose tissue and its deleterious adipokines. Na+/H+ exchanger 1 inhibition in the heart and lungs reduces sodium-induced calcium overload and pulmonary hypertension, respectively.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":" ","pages":"e23"},"PeriodicalIF":0.0,"publicationDate":"2022-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/21/25/cfr-08-e23.PMC9272408.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40612958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

In-hospital Initiation and Up-titration of Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction. 指南指导的心力衰竭射血分数降低的药物治疗的医院内启动和上调。

IF 4.2

Cardiac Failure Review Pub Date : 2022-06-24 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2022.08

Zachary L Cox, Shuktika Nandkeolyar, Andrew J Johnson, JoAnn Lindenfeld, Aniket S Rali

引用次数: 0

The Role of Cardiac Imaging in Heart Failure with Reduced Ejection Fraction. 心脏造影在心力衰竭伴射血分数降低中的作用。

Cardiac Failure Review Pub Date : 2022-06-24 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2021.33

Rebecca C Gosling, Abdallah Al-Mohammad

引用次数: 1

Biomarkers in Heart Failure with Preserved Ejection Fraction. 保留射血分数的心力衰竭的生物标志物。

Cardiac Failure Review Pub Date : 2022-06-23 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2021.37

Antoni Bayes-Genis, Germán Cediel, Mar Domingo, Pau Codina, Evelyn Santiago, Josep Lupón

{"title":"Biomarkers in Heart Failure with Preserved Ejection Fraction.","authors":"Antoni Bayes-Genis, Germán Cediel, Mar Domingo, Pau Codina, Evelyn Santiago, Josep Lupón","doi":"10.15420/cfr.2021.37","DOIUrl":"https://doi.org/10.15420/cfr.2021.37","url":null,"abstract":"Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous disorder developing from multiple aetiologies with overlapping pathophysiological mechanisms. HFpEF diagnosis may be challenging, as neither cardiac imaging nor physical examination are sensitive in this situation. Here, we review biomarkers of HFpEF, of which the best supported are related to myocardial stretch and injury, including natriuretic peptides and cardiac troponins. An overview of biomarkers of inflammation, extracellular matrix derangements and fibrosis, senescence, vascular dysfunction, anaemia/iron deficiency and obesity is also provided. Finally, novel biomarkers from -omics technologies, including plasma metabolites and circulating microRNAs, are outlined briefly. A cardiac-centred approach to HFpEF diagnosis using natriuretic peptides seems reasonable at present in clinical practice. A holistic approach including biomarkers that provide information on the non-cardiac components of the HFpEF syndrome may enrich our understanding of the disease and may be useful in classifying HFpEF phenotypes or endotypes that may guide patient selection in HFpEF trials.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":" ","pages":"e20"},"PeriodicalIF":0.0,"publicationDate":"2022-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/58/bd/cfr-08-e20.PMC9253965.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40492041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Co-occurrence of Myocardial Sarcoidosis and Left Ventricular Non-compaction in a Patient with Advanced Heart Failure. 晚期心力衰竭患者心肌结节病和左心室非压实性共存的研究。

Cardiac Failure Review Pub Date : 2022-06-20 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2022.05

Anupam A Kumar, Lena E Tran, Aniket S Rali, Alexander Perez, Robert Hoffman, Kelly Schlendorf

{"title":"Co-occurrence of Myocardial Sarcoidosis and Left Ventricular Non-compaction in a Patient with Advanced Heart Failure.","authors":"Anupam A Kumar, Lena E Tran, Aniket S Rali, Alexander Perez, Robert Hoffman, Kelly Schlendorf","doi":"10.15420/cfr.2022.05","DOIUrl":"https://doi.org/10.15420/cfr.2022.05","url":null,"abstract":"A 46-year-old man with systolic heart failure, end-stage renal disease on dialysis, ventricular tachycardia and pulmonary sarcoidosis presented with decompensated heart failure and cardiogenic shock of unknown aetiology. The hospital course was complicated by worsening shock requiring inotropic and mechanical circulatory support, as well as eventual dual heart and kidney transplantation. Cardiac imaging was used to assess the aetiology of the patient's non-ischaemic cardiomyopathy, including a PET scan and cardiac MRI. Imaging demonstrated findings consistent with left ventricular non-compaction, but was inconclusive for cardiac sarcoidosis. After eventual heart transplantation, histopathology of the patient's explanted heart showed evidence of both non-compaction and cardiac sarcoidosis. In this case report, the authors review the pathophysiology of both cardiac sarcoidosis and left ventricular non-compaction, and highlight a multimodality approach to the diagnosis of non-ischaemic cardiomyopathy.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":" ","pages":"e19"},"PeriodicalIF":0.0,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/bf/cfr-08-e19.PMC9247987.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40577351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Utility of HeartLogic, a Multiparametric Telemonitoring System, in Heart Failure. HeartLogic是一种多参数远程监测系统，在心力衰竭中的临床应用。

Cardiac Failure Review Pub Date : 2022-04-21 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2021.35

Juan Carlos López-Azor, Noelia de la Torre, María Dolores García-Cosío Carmena, Pedro Caravaca Pérez, Catalina Munera, Irene MarcoClement, Rocío Cózar León, Jesús Álvarez-García, Marta Pachón, Fernando Arribas Ynsaurriaga, Rafael Salguero Bodes, Juan Francisco Delgado Jiménez, Javier de Juan Bagudá

{"title":"Clinical Utility of HeartLogic, a Multiparametric Telemonitoring System, in Heart Failure.","authors":"Juan Carlos López-Azor, Noelia de la Torre, María Dolores García-Cosío Carmena, Pedro Caravaca Pérez, Catalina Munera, Irene MarcoClement, Rocío Cózar León, Jesús Álvarez-García, Marta Pachón, Fernando Arribas Ynsaurriaga, Rafael Salguero Bodes, Juan Francisco Delgado Jiménez, Javier de Juan Bagudá","doi":"10.15420/cfr.2021.35","DOIUrl":"10.15420/cfr.2021.35","url":null,"abstract":"Telemonitoring through multiple variables measured on cardiac devices has the potential to improve the follow-up of patients with heart failure. The HeartLogic algorithm (Boston Scientific), implemented in some implantable cardiac defibrillators and cardiac resynchronisation therapy, allows monitoring of the nocturnal heart rate, respiratory movements, thoracic impedance, physical activity and the intensity of heart tones, with the aim of predicting major clinical events. Although HeartLogic has demonstrated high sensitivity for the detection of heart failure decompensations, its effects on hospitalisation and mortality in randomised clinical trials has not yet been corroborated. This review details how the HeartLogic algorithm works, compiles available evidence from clinical studies, and discusses its application in daily clinical practice.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"8 ","pages":"e13"},"PeriodicalIF":0.0,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ee/e5/cfr-08-e13.PMC9062709.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10615623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Endpoints in Heart Failure Drug Development. 心力衰竭药物开发的终点。

Cardiac Failure Review Pub Date : 2022-01-18 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2021.13

Aliza Hussain, Arunima Misra, Biykem Bozkurt

{"title":"Endpoints in Heart Failure Drug Development.","authors":"Aliza Hussain, Arunima Misra, Biykem Bozkurt","doi":"10.15420/cfr.2021.13","DOIUrl":"https://doi.org/10.15420/cfr.2021.13","url":null,"abstract":"Heart failure (HF) is a major health problem worldwide. The development of effective drug and/or device therapy is crucial to mitigate the significant morbidity, mortality and healthcare costs associated with HF. The choice of endpoint in clinical trials has important practical and clinical implications. Outcomes of interest including mortality and HF hospitalisations provide robust evidence for regulatory approval granted there is sufficiency of safety data. At the same time, it is important to recognise that HF patients experience significant impairments in functional capacity and quality of life, underscoring the need to incorporate parameters of symptoms and patient-reported outcomes in clinical trials. In this review, the authors summarise the evolution and definition of cardiovascular endpoints used in clinical trials, discuss approaches to study design to allow the incorporation of mortality, morbidity and functional endpoints and, finally, examine the current challenges and suggest steps for the development of cardiovascular endpoints that are effective, meaningful and meet the needs of all relevant stakeholders, including patients, physicians regulators and sponsors.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":" ","pages":"e01"},"PeriodicalIF":0.0,"publicationDate":"2022-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8c/67/cfr-08-e01.PMC8790723.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39744489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7